Protagonist Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Protagonist Therapeutics, Inc.
The partners’ orally administered IL-23R inhibitor met all primary and secondary endpoints in a Phase IIb plaque psoriasis trial, justifying advancement to Phase III even though its efficacy fell short of available injectables according to cross-trial comparisons.
The company’s late-breaker data suggests it is on the path to success in polycythemia vera, but cancer fears must be addressed with ongoing longer-term study.
Public Company Edition: ImmunoGen received the first $75m under a $175m term loan, while Protagonist raised $100m in a follow-on offering, but companies with bankruptcy filings and job cuts outpaced those accessing new capital by a wide margin in late March and early April.
- Drug Discovery Tools
- Large Molecule
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.